{"id":876219,"date":"2025-08-15T07:33:49","date_gmt":"2025-08-15T11:33:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/"},"modified":"2025-08-15T07:33:49","modified_gmt":"2025-08-15T11:33:49","slug":"plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/","title":{"rendered":"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">HOUSTON, Aug.  15, 2025  (GLOBE NEWSWIRE) &#8212; \u00a0<u>Plus Therapeutics, Inc.<\/u> (Nasdaq:\u00a0<u>PSTV<\/u>) (\u201cPlus\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders\u2019 equity of $3\u00a0million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the \u201cEquity Rule\u201d), as of June\u00a030, 2025. The Equity Rule requires listed companies to maintain a minimum of $2.5\u00a0million in stockholders\u2019 equity.<\/p>\n<p align=\"justify\">As previously reported, on June\u00a03, 2025, the Nasdaq Listing Qualifications Department (the \u201cStaff\u201d) notified the Company that, as of March\u00a031, 2025, the Company no longer satisfied the Equity Rule.\u00a0Insofar as the Company was subject to a Mandatory Panel Monitor, as that term is defined under Nasdaq Listing Rule 5815(d)(4)(C), through March\u00a06, 2026, with respect to the Equity Rule in particular, the Staff issued a delist determination following such\u00a0non-compliance.\u00a0On June\u00a010, 2025, the Company timely requested a hearing before the Nasdaq Hearings Panel (the \u201cPanel\u201d), which stayed any further action by the Staff. The hearing was held on July\u00a015, 2025.<\/p>\n<p align=\"justify\">As previously disclosed, on July\u00a022, 2025, the Company was notified by Nasdaq that the Panel had granted the Company\u2019s request for an extension to evidence compliance with the Equity Rule subject to the Company\u2019s satisfaction of certain conditions.<\/p>\n<p align=\"justify\">As reflected in the Form\u00a010-Q\u00a0for the quarter ended June\u00a030, 2025 filed August 14, 2025, the Company reported stockholders\u2019 equity in excess of $2.5\u00a0million and therefore satisfied the Equity Rule as of June\u00a030, 2025. The Company awaits Nasdaq\u2019s confirmation that it has evidenced compliance with the Equity Rule.<\/p>\n<p align=\"justify\">\n        <strong>About Plus Therapeutics<\/strong><br \/>\n        <br \/>Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q31XnkBbnZZuKN28LSwlAmQQPPPCBtjZz0In1seLywEVPTy_OM39NWnHLqkBX5wptV-uB25Vg8QUxO6TJ2YDLyd-nS-rLpoUV5ebDWUWpRWFhVtN10eHESADlgmH3GJB\" rel=\"nofollow\" target=\"_blank\">https:\/\/plustherapeutics.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>CORE IR<br \/>investor@plustherapeutics.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWZjNzA3NTAtODI3ZC00MGYzLWI1OWMtYmI2OTc0MzBiZGQ2LTEwMTYzNzgtMjAyNS0wOC0xNS1lbg==\/tiny\/Plus-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (\u201cPlus\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders\u2019 equity of $3\u00a0million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the \u201cEquity Rule\u201d), as of June\u00a030, 2025. The Equity Rule requires listed companies to maintain a minimum of $2.5\u00a0million in stockholders\u2019 equity. As previously reported, on June\u00a03, 2025, the Nasdaq Listing Qualifications Department (the \u201cStaff\u201d) notified the Company that, as of March\u00a031, 2025, the Company no longer satisfied the Equity Rule.\u00a0Insofar as the Company was subject to a Mandatory Panel Monitor, as that term is defined under Nasdaq Listing Rule 5815(d)(4)(C), through March\u00a06, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-876219","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (\u201cPlus\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders\u2019 equity of $3\u00a0million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the \u201cEquity Rule\u201d), as of June\u00a030, 2025. The Equity Rule requires listed companies to maintain a minimum of $2.5\u00a0million in stockholders\u2019 equity. As previously reported, on June\u00a03, 2025, the Nasdaq Listing Qualifications Department (the \u201cStaff\u201d) notified the Company that, as of March\u00a031, 2025, the Company no longer satisfied the Equity Rule.\u00a0Insofar as the Company was subject to a Mandatory Panel Monitor, as that term is defined under Nasdaq Listing Rule 5815(d)(4)(C), through March\u00a06, &hellip; Continue reading &quot;Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T11:33:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements\",\"datePublished\":\"2025-08-15T11:33:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/\"},\"wordCount\":362,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/\",\"name\":\"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU=\",\"datePublished\":\"2025-08-15T11:33:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/","og_locale":"en_US","og_type":"article","og_title":"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - Market Newsdesk","og_description":"HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (\u201cPlus\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders\u2019 equity of $3\u00a0million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the \u201cEquity Rule\u201d), as of June\u00a030, 2025. The Equity Rule requires listed companies to maintain a minimum of $2.5\u00a0million in stockholders\u2019 equity. As previously reported, on June\u00a03, 2025, the Nasdaq Listing Qualifications Department (the \u201cStaff\u201d) notified the Company that, as of March\u00a031, 2025, the Company no longer satisfied the Equity Rule.\u00a0Insofar as the Company was subject to a Mandatory Panel Monitor, as that term is defined under Nasdaq Listing Rule 5815(d)(4)(C), through March\u00a06, &hellip; Continue reading \"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-15T11:33:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements","datePublished":"2025-08-15T11:33:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/"},"wordCount":362,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/","name":"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU=","datePublished":"2025-08-15T11:33:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzEzMSM3MTAxNDE3IzIwMDQ4MDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-million-in-compliance-with-nasdaq-equity-requirements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Plus Therapeutics Reports Stockholders\u2019 Equity\u00a0in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=876219"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876219\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=876219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=876219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=876219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}